ArticleJournal of neuro-oncology2025
Clinical, pathological, radiological features and prognosis of epithelioid glioblastoma: a retrospective single center study.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEpithelioid glioblastoma (eGBM) is a rare variant of glioblastoma (GBM). Due to the limited number of reported cases, our understanding of eGBM remains constrained. The updated definition of GBM has further highlighted the need for more comprehensive studies on this rare subtype. MATERIALS AND
methodsThis study retrospectively reviewed 17 cases of eGBM diagnosed at a single center between 2016 and 2023. Detailed clinicopathological data were analyzed, including clinical presentation, pathological characteristics, radiological findings, treatment modalities, and patient outcomes.
resultsThe cohort comprised 8 females and 9 males with an average age of 40.88 years. Tumors were predominantly located in the supratentorial region (64.71%, 11/17), while uncommon locations included the basal ganglia (11.76%, 2/17), sellar region (5.88%, 1/17), and pineal region (5.88%, 1/17). Multi-modal MRI scans revealed consistent features such as T1 contrast enhancement, elevated Cho/NAA ratios, increased nCBF and nCBV values, and disruption of white matter tracts. Additional radiological findings included mild peritumoral edema (64.71%, 11/17), hemorrhage (17.65%, 3/17), dural tail sign (35.29%, 6/17), and necrosis (29.41%, 5/17). Pathologically, all cases exhibited microvascular proliferation, IDH1 wild-type status, and high Ki-67 indices. Other notable findings included EMA positivity or partial positivity (47.06%, 8/17), INI-1 positivity (100%, 11/11), BRAF-V600E mutation (76.47%, 13/17), necrosis (82.35%, 14/17), and leptomeningeal dissemination (29.41%, 5/17). All patients underwent gross total resection (GTR), and 14 received adjuvant chemoradiotherapy. The median overall survival was 12.53 months. Two patients who received TTFields therapy survived for 12.53 and 16.63 months, respectively. Two patients treated with BRAF-V600E-targeted therapy had survival times of 16.93 and 22.67 months, respectively.
conclusioneGBM is a distinct and aggressive variant of GBM characterized by shorter survival times. The variability in MRI features and unusual tumor locations can lead to misdiagnosis, which multi-modal MRI may help mitigate. High frequencies of BRAF V600E mutations and INI-1 positive expression are observed in eGBM. Combined therapies, including TTFields and BRAF V600E-targeted treatments, appear to be associated with improved outcomes.
Indexed as
Identifiers
40266499What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.